United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - mercaptopurine - tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (germany - mercaptopurine - tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - mercaptopurine - capsule - 20mg

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - mercaptopurine monohydrate, quantity: 50 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; stearic acid; magnesium stearate; hydrolysed maize starch - indications as at 5 march 2004: treatment of leukemia. it is of value in remission induction and is particularly indicated for maintenance therapy in acute lymphoblastic leukemia and acute myelogenous leukemia. mercapt is also used in the treatment of chronic granulocytic leukaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - mercaptopurine monohydrate, quantity: 50 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; stearic acid; magnesium stearate; hydrolysed maize starch - indications as at 5 march 2004: treatment of leukemia. it is of value in remission induction and is particularly indicated for maintenance therapy in acute lymphoblastic leukemia and acute myelogenous leukemia. puri-nethol is also used in the treatment of chronic granulocytic leukaemia.

United States - English - NLM (National Library of Medicine)

stason pharmaceuticals, inc. - mercaptopurine (unii: e7wed276i5) (mercaptopurine anhydrous - unii:pkk6muz20g) - purinethol is indicated for treatment of adult and pediatric patients with acute lymphoblastic leukemia (all) as part of a combination chemotherapy maintenance regimen. none. purinethol can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . pregnant women who receive mercaptopurine have an increased incidence of miscarriage and stillbirth (see data) . advise pregnant women of the potential risk to a fetus. the estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. women receiving mercaptopurine in the first trimester of pregnancy have an increased incidence of miscarriage; the risk of malformation in offspring surviving first trimester exposure is not known. in a series of 28 women receiving mercaptopurine after the first trimester of pregnancy, 3 mothers died prior to delivery, 1 delivered a stillborn child, and 1 aborted; there were no cases of macroscopically abnormal fetuses. mercaptopurine was embryo-lethal and teratogenic in several animal species (rat, mouse, rabbit, and hamster) at doses less than the recommended human dose. there are no data on the presence of mercaptopurine or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with purinethol and for 1 week after the last dose. purinethol can cause fetal harm when administered to pregnant women [see use in specific populations (8.1)] . verify the pregnancy status in females of reproductive potential prior to initiating purinethol  [see use in specific populations (8.1)] . advise females of reproductive potential to use effective contraception during treatment with purinethol and for 6 months after the last dose. based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with purinethol and for 3 months after the last dose [see nonclinical toxicology (13.1)] . based on findings from animal studies, purinethol can impair female and male fertility [see nonclinical toxicology (13.1)] . the long-term effects of mercaptopurine on female and male fertility, including the reversibility have not been studied. safety and effectiveness of purinethol has been established in pediatric patients. use of purinethol in pediatrics is supported by evidence from the published literature and clinical experience. symptomatic hypoglycemia has been reported in pediatric patients with all receiving mercaptopurine. reported cases were in pediatrics less than 6 years of age or with a low body mass index. clinical studies of mercaptopurine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or another drug therapy. use the lowest recommended starting dosage for purinethol or increase the dosing interval to every 36-48 hours in patients with renal impairment (clcr less than 50 ml/min). adjust the dose to maintain absolute neutrophil count (anc) at a desirable level and for adverse reactions [see dosage and administration (2.3)] . use the lowest recommended starting dosage for purinethol in patients with hepatic impairment. adjust the dose to maintain absolute neutrophil count (anc) at a desirable level and for adverse reactions [see dosage and administration (2.3)] .

United States - English - NLM (National Library of Medicine)

nova laboratories, ltd - mercaptopurine (unii: e7wed276i5) (mercaptopurine anhydrous - unii:pkk6muz20g) - mercaptopurine 20 mg in 1 ml - purixan is indicated for the treatment of patients with acute lymphoblastic leukemia (all) as part of a combination chemotherapy maintenance regimen. read these instructions for use before you start taking purixan, and each time you get a refill. there may be new information. this information does not take the place of talking to your healthcare provider about your medical condition or your treatment. important information about measuring purixan oral suspension • always use the oral dispensing syringe provided with your purixan oral suspension to make sure you measure the right amount. • you will be provided: - 1 bottle of purixan oral suspension - 1 bottle adapter - 2 oral dispensing syringes (one 1 ml and one 5 ml) if you did not receive an oral dispensing syringe with your purixan oral suspension, ask your pharmacist to give you one. you will need disposable gloves. - do not forcefully push on the plunger. - do not squirt the medicine to the back of your mouth or throat. this may cause you to ch

Ireland - English - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - mercaptopurine monohydrate - tablet - 50 milligram(s) - mercaptopurine

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - mercaptopurine monohydrate - tablet - 50 milligram(s) - mercaptopurine

Ireland - English - HPRA (Health Products Regulatory Authority)

fontus health limited - mercaptopurine - tablet - 50 milligram(s) - purine analogues; mercaptopurine